Abstract
Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics. Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.
Lingua originale | English |
---|---|
pagine (da-a) | 9-20 |
Numero di pagine | 12 |
Rivista | ACTAS DERMO-SIFILOGRAFICAS |
Volume | 105 |
DOI | |
Stato di pubblicazione | Pubblicato - 2014 |
Keywords
- Arthritis
- Atherosclerosis
- Brodalumab
- IL-17
- Ixekizumab
- Obesity
- Psoriasis
- Secukinumab